Navigation Links
Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
Date:10/29/2009

CAMBRIDGE, Mass., Oct. 29 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that Novartis Pharma AG has decided not to exercise its option to license IDX184, a novel liver-targeted prodrug of 2'-methyl guanosine nucleotide, for the treatment of HCV. As a result, Idenix retains the worldwide rights to develop, commercialize and license IDX184 without any further obligation to Novartis.

"As we continue to develop IDX184, we look forward to seeking a partner that will assist us in maximizing the value of this asset," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix.

About IDX184

IDX184 is a novel, liver-targeted 2'-methyl guanosine nucleotide prodrug, which includes Idenix's proprietary liver-targeting technology. This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic side effects with low, once-daily dosing.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
4. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
5. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
6. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
7. Idenix Pharmaceuticals Reports First Quarter Financial Results
8. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
9. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
10. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
11. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
(Date:12/19/2014)... Decision Resources Group finds that the Latin ... percent compound annual growth rate through 2023. This is ... the increasing adoption of dental implants. Growing aesthetic consciousness ... spur demand for dental biomaterials because they can improve ... Other key findings from Decision Resources Group,s ...
(Date:12/19/2014)... ME (PRWEB) December 18, 2014 Ed ... director of the Center for Excellence in the Neurosciences ... New England, has been selected as a member of ... is the first neuroscientist from Maine to receive this ... nonprofit organization supported entirely by the Dana Foundation. ...
(Date:12/19/2014)... San Diego, CA (PRWEB) December 18, 2014 ... announces a limited time special on Sartorius Biohit ... 1 Free on mLINE pipettes, Picus Electronic Pipette Trade-in ... recommended by Health and Safety officers around the world. ... repetitive manual pipetting. Other features include:, , ...
Breaking Biology Technology:Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... CAMBRIDGE, Mass., Dec. 17 Genzyme Corp.,(Nasdaq: ... and Drug Administration,(FDA) has approved a supplemental indication ... in combination with radioiodine to ablate,or destroy, the ... their,cancerous thyroids removed. Remnant ablation is a procedure ...
... GENEVA, Switzerland, Dec. 17 /PRNewswire-FirstCall/ - Anavex Life,Sciences ... of,Dr. Cameron Durrant to its Board of Directors. ... Global Strategic Marketing at Johnson,& Johnson (NYSE: ... privileged to welcome Dr. Durrant to our,Board," said ...
... England, December 17 , - New Deal ... its,Therapeutic Antibody Pipeline, Oxford Genome Sciences (UK) ... a strategic collaboration with Amgen to discover, develop ... cancer.,This new collaboration will enable OGeS to further ...
Cached Biology Technology:Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 2Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 3Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation 4Anavex strengthens Board of Directors 2Anavex strengthens Board of Directors 3Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 2Oxford Genome Sciences and Amgen to Jointly Discover Novel Therapeutic Antibodies in Cancer 3
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
... professor of medicine at National Jewish Health, has ... lipids and related compounds that can inhibit inflammation ... by influenza and respiratory syncytial virus (RSV). Over ... several scientific papers describing a naturally occurring lipid ...
... bunch of inanimate chemical compounds, the nucleic and amino acids ... have put on quite a soap opera for biologists since ... A new study, a highlight in the March issue of ... In TV listings the series would be described this ...
... considered to be the principle vectors of West Nile virus ... summer. In addition, these mosquitoes may also serve as overwintering ... mosquito to egg, then larva, and then adult. To ... in mosquitoes in the field and in the lab, and ...
Cached Biology News:Does the villainous 'selfish' gene undermine genome's police? 2Does the villainous 'selfish' gene undermine genome's police? 3West Nile virus passes from female to eggs, but less so from larvae to adults 2
... with PowerPac 3000 power supply, 220-240 V, ... by liquid-phase isoelectric focusing (IEF). The system ... standard (60 ml) focusing chambers, chassis, harvesting ... power supply, 10 ml Bio-Lyte ampholytes (pH ...
Recognizes Human Connexin 45. Due to sequence homologies, this antibody is also expected to react with canine (100% homology) and mouse (92% homology) Connexin 45. Also confirmed to work on rat C6 c...
... Chromogen system consists of [5-Bromo-4-Chloro-3-,Indolyl ... a single component,solution. The ready-to-use ... presence of alkaline phosphatase to ... minimal background noise. ,The System ...
... microplate readers combines reagent dispensing with fluorescence, ... easy-to-use platform for the complete range of ... and adaptability of the Infinite 200 series ... monochromator (M200) or filter (F200) system and ...
Biology Products: